

Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting

Gereon Nelles · Lukas Schmitt · Thomas Humbert · Veit Becker ·
Petra Sandow · Karin Bornhoevd · Dirk Fritzsche · Barbara Schäuble ·
on behalf of the TOPMATMIG-0001 investigators

Received: 16 August 2009 / Accepted: 28 September 2009 / Published online: 6 November 2009
© Springer-Verlag 2009

Abstract The majority of patients with migraine headaches are treated in non-specialized institutions though data on treatment outcomes are largely derived from tertiary care centers. The current non-interventional study explores efficacy and tolerability outcomes of patients with episodic migraines receiving topiramate as preventive agent in a general practice setting. A total of 366 patients (87% female, mean age 41.8 ± 11.6 years) were eligible for migraine prevention and treated with flexible dose topiramate for 6 months (core phase), and optionally for a total of 12 months (follow-up phase). Overall, 261 patients (77.7% of safety analysis set, SAF) completed the core phase. Reasons for discontinuation

included adverse events (2.1%), lost to follow-up (1.8%), other reasons (1.5%), and end of therapy (0.3%) though in the majority of patients who discontinued no reasons were listed. The median daily dose at endpoint was 50 mg/day (range, 25–187.5 mg/day). The median days with migraine headaches decreased from 6.0 to 1.2 days ($p < 0.001$), median pain intensity score decreased from 17.0 to 3.2 points ($p < 0.001$). In women with reported menstruation-associated migraine, the median number of migraine attacks decreased from 4.0 to 0.9 ($p < 0.001$). Absenteeism as well as triptan use decreased significantly, and significant improvements in activities of daily living and quality of life were reported. The most frequently reported AEs were paraesthesia (4.2%) and nausea (3%). Results suggest that migraine prevention with topiramate in a general practice is generally well tolerated and associated with a significant improvement in migraine headaches and related functional impairment.

G. Nelles
Neurology Outpatient Clinic, St. Elisabeth Krankenhaus Köln,
50935 Cologne, Germany

L. Schmitt
Gesundheitshaus Karl Schneider Passagen, Heussweg 37,
20255 Hamburg-Eimsbüttel, Germany

T. Humbert · V. Becker
Private Practice, Kümmellstr. 1, 20249 Hamburg, Germany

P. Sandow
Private Practice, Reichsstraße 81, 14052 Charlottenburg,
Berlin, Germany

K. Bornhoevd · B. Schäuble
Janssen-Cilag EMEA, Johnson and Johnson Platz 1,
41470 Neuss, Germany

D. Fritzsche
MEDIDATA GmbH, Max-Stromeyer-Street 166,
78467 Constance, Germany

G. Nelles (✉)
Neurologische Praxis, St. Elisabeth Krankenhaus,
Werthmannstrasse 1c, 50935 Köln, Germany
e-mail: gereon.nelles@uni-duisburg-essen.de

Keywords Migraine prevention · Topiramate ·
Open label study · Menstruation

Abbreviations

AE	Adverse event
CRF	Case report form
CP	Core phase
EAS	Efficacy analysis set
FUAS	Follow up analysis set
EFF	Efficacy population
HIT	Headache impact test
IHS	International headache society
IQR	Interquartile range
LOCF	Last observation carried forward
SAF	Safety population
SD	Standard deviation

Introduction

Migraine is a common neurological disorder affecting approximately 12 to 14% of all women and 6 to 8% of all men in western societies [1, 2]. It is reported that 43% of women and 18% of men suffer from migraine at some point in their lives [3, 4]. Due to the negative impact on quality of life, daily activity and work-related productivity, timely diagnosis, and effective management of the patient is important [5–7]. Next to non-pharmacological interventions, effective acute and preventive treatments play an important role [8]. Migraine prevention not only reduces the frequency, severity, and duration of attacks, but was shown to reduce migraine-related socio-economic burden [9]. Pharmacological prevention of migraine is recommended by several professional societies if patients fulfill criteria for preventive treatment [10]. Multiple effective drugs are available, however, they differ in the level of scientific evidence to support their use in migraine prevention as well as in their clinical profile. Preventive medication frequently used and recommended by professional bodies include beta-blockers, calcium channel blockers, tricyclic antidepressants, or anti-epileptic drugs, such as valproate and topiramate [11–16]. Topiramate is a fructopyranose sulfamate with proven efficacy in migraine prevention. This was demonstrated in several randomized, controlled clinical trials [12, 13, 18]. Most commonly, treatments are used in monotherapy, however, there is some emerging data that in certain individuals add-on therapy might be appropriate [17].

Despite considerable burden of disease and available class I evidence, only 1 in 5 patients who fulfill the criteria for preventive migraine therapy are treated and considerable underrecognition of the disease itself is reported [19].

Though general practitioners play an important role in disease recognition and initial treatment [20], there are only few data on patient outcomes with topiramate derived from non-specialized centers [21]. Therefore, the present study is designed to explore tolerability and efficacy outcomes in outpatients treated with topiramate for migraine prevention in a naturalistic setting.

Methods

Study design

This was a prospective, multicenter non-interventional study carried out between February 2006 and December 2007 in Germany. Patients were followed-up during a 6 months core phase with an optional follow-up for up to 12 months in total. The decision to extend the treatment period from 6 to 12 months was based on physicians' and patients' assessments of therapy at month 6. No formal

criteria were established. Patients were evaluated at baseline, after approximately 2, 4, 8, 12 weeks, and after 6 months with optional follow-up after 9 and 12 months. Patients' demographics, disease characteristics including frequency of migraine attacks, migraine auras and associated symptoms, pain intensity, quality of life, absenteeism, previous and currently used preventive agents, type and frequency of intake of acute medication, other concomitant medication, and adverse events (AEs) were recorded in the electronic case report form (CRF). Data on frequency, severity, and symptoms of all headaches or auras, and the use of acute medications were based on patient's diaries, which were transcribed by the investigator into the patient's CRF. All visits were office-based exception except for Visit 2 (2 weeks) and Visit 4 (8 weeks), which were optional and by phone.

Patient selection

Patients were selected from 183 non-academic neurology, anesthesiology, or general practices in Germany. Patients, aged 18 years and older were documented if they carried a diagnosis of episodic migraine headaches and their diagnosis was based on the International Headache Society (IHS) criteria http://www.i-h-s.org/upload/ct_clas/ihc_II_main_no_print.pdf. The patients were prospectively followed-up for 6 and optionally for 12 months if migraine preventive therapy was indicated based on guidelines published by the German Neurological Society (DGN) <http://www.ehf-org.org/Documents/Germany.pdf> and the German Society for Headache (DGKM) [10]. Migraine headache, migraine attacks, and auras were defined based on the IHS definitions. Patients with known hypersensitivity or other contraindications prohibiting topiramate therapy were excluded from participation.

Treatment

Topiramate (Topamax[®] Migräne; Janssen-Cilag GmbH, Germany) was recommended to be taken based on the summary of product characteristics. Titration rate and final dose were guided by the patient's clinical response to topiramate therapy.

Concomitant therapies

Patients were allowed to take acute rescue medications, such as analgesics, non-steroidal anti-inflammatory drugs, triptans, ergotamine derivatives, opioids, and other rescue medication during any phase in the study. The use of acute rescue medication had to be recorded in the patient diary together with disease-related information (e.g. migraine attack information).

Ethics

The study was conducted in accordance with the “Empfehlungen zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen (Recommendation for the planning, implementation and evaluation of non-interventional studies with medicinal products)” of the BfArM (Federal Institute for Drugs and Medical Devices) dated 12 November 1998 and the “Notice to Marketing Authorisation Holders—Pharmacovigilance Guidelines” issued by the EMEA (European Agency for the Evaluation of Medicinal Products). Janssen-Cilag has notified the BfArM about the conduct of the study. An independent ethics committee (Freiburg, Germany) evaluated the study protocol and granted approval for study conduct.

Outcome measures

The primary objective of the study was to explore efficacy and tolerability outcomes of flexibly dosed topiramate in routine clinical practice. Exploratory efficacy outcome measures included the change in the median number of monthly migraine attacks from baseline to the last visit of the core phase (6 months) and to the last visit of the optional follow-up phase (for a maximum of 12). In addition, changes in monthly migraine days, changes in frequency of migraine attacks, changes in pain intensity score were captured; the percentage of patients with $\geq 50\%$, $\geq 75\%$, and $\geq 90\%$ reduction in the mean number of monthly migraine attacks (categorical responder rates). Types and frequencies of AEs, the dosage of topiramate in daily practice, and the impact of migraine on activities of daily living and on the quality of life (HIT-6TM) were analyzed. Impairment of daily life was measured with the impairment score. The impairment score was calculated as (days with severe impairment $\times 3$) + (days with moderate impairment $\times 2$) + (days with slight impairment $\times 1$), normalized to 28 days. The HIT-6TM is a tool to measure the impact of headaches on daily life. The questionnaire consists of 6 questions with a 5-point scale (“never”, “rarely”, “sometimes”, “very often”, and “always”). The sum of the total score ranges between 36 (no impact) and 78 (severe impact).

Statistical analyses and data management

Statistics

All statistical tests were exploratory. No adjustment for multiple testing was performed. Last observation carried forward (LOCF) analyses were performed for treatment effect parameters using the last available post-dose value of the respective parameter as the endpoint of analysis. No other imputation of data was performed. Continuous

variables were described by the total number of observations (N), minimum, maximum, mean, standard deviation (SD), median, and interquartile range (IQR). Categorical variables were described by the total number of patients, and by the number and the proportion of patients for each category. Changes from baseline were analyzed by exploratory Wilcoxon signed rank tests (significance level: 0.05). Data regarding AEs, previous and concomitant diseases, and surgical procedures were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 10.1. The incidence of AEs was computed together with its binomial 95% confidence interval.

Data sets analyzed

Available data of all patients were listed in patient data listings. For analysis, the following populations were defined: a *Safety population* (SAF), which included all patients for whom documentation was started and for whom the intake of at least one dose of topiramate was documented, and a *Treatment effect population* (EFF), which included all SAF patients for whom at least one treatment effect variable was documented after the start of topiramate treatment. In addition, a subanalysis was stipulated to compare women with menstruation-associated migraine at baseline versus women with migraines not associated with menstruation at baseline. An overview on the study populations is given in Fig. 1.




Fig. 1 Flowchart showing an overview on the study population

Results

A total of 336 out of 373 patients evaluated received topiramate (SAF). In 34 patients, no post-baseline efficacy outcomes data were documented. Based on this, the EFF-analysis comprised 302 patients (Fig. 1). A total of 261 patients (77.7% of SAF) completed the 6 months observational period (core phase), whereas 75 patients (22.3% of SAF) discontinued prematurely. Reasons for premature discontinuation were: AEs ($N = 7$, 2.1% of SAF), lost to follow-up ($N = 6$, 1.8%), other reasons ($N = 5$, 1.5%), and end of therapy ($N = 1$, 0.3%). In the majority of patients though, a reason for discontinuation was not obtainable. A total of 203 patients (60.4% of SAF) had data available at Visit 7 (Month 9) and 183 patients (54.5% of SAF) completed the 12 months.

Baseline demographics, disease characteristics, and previous treatment

Pertinent baseline data and disease characteristics of the 302 patients treated in the core phase (ITT-analysis) are summarized in Tables 1 and 2. As much as 29.5% of patients reported migraine headaches with auras and in 36.8% of women menstruation-associated migraines were reported.

In the EFF, 139 patients (46.0% of EFF) had received migraine preventive treatment in the past (Table 3). As much as 82.7% ($N = 115$) had been exposed to 1 or 2 therapeutic attempts with beta blockers and 5.0% even to 3

Table 1 Demographic data

	SAF $N = 336$	EFF $N = 302$
Gender (N , %)		
Female	292 (76.9)	266 (88.1)
Male	44 (13.1)	36 (11.9)
Age (years)		
Mean \pm SD	41.8 \pm 11.6	41.5 \pm 11.4
Median (range)	42 (18, 71)	42 (18, 71)
Height (cm)		
Mean \pm SD	168.6 \pm 7.1	168.5 \pm 7.0
Median (range)	168 (150, 193)	168 (150, 193)
Weight (kg)		
Mean \pm SD	69.1 \pm 11.6	68.6 \pm 11.3
Median (range)	68 (46, 110)	67 (46, 107)
BMI (kg/m^2)		
Mean \pm SD	24.3 \pm 3.7	24.2 \pm 3.6
Median (range)	23.5 (17.7, 41.3)	23.4 (17.7, 38.2)

Percentages relate to the number of patients in the respective population

Table 2 Disease characteristics

	SAF $N = 336$	EFF $N = 302$
Age at first diagnosis of migraine (years)		
N	328	295
Mean \pm SD	24.1 \pm 9.0	24.0 \pm 8.6
Median (range)	22 (8, 53)	22 (8, 53)
Time since diagnosis (years)		
N	328	295
Mean \pm SD	17.5 \pm 11.0	17.4 \pm 10.7
Median (range)	17 (0, 52)	17 (0, 52)
Migraine associated with menstruation (women only) (N , % ^a)		
No	183 (62.7)	167 (62.8)
Yes	107 (36.6)	98 (36.8)
Aura (N , % ^b)		
No	234 (69.6)	213 (70.5)
Yes	102 (30.4)	89 (29.5)

^a Percentages relate to the number of female patients in the respective population

^b Percentages relate to the number of patients in the respective population

to 4 attempts. Antidepressants were used at least once by 43 patients (30.9% of pretreated EFF patients). As much as 37 patients (26.6%) used Ca^{2+} -channel blockers and 23 patients (16.5%) used anticonvulsant drugs other than topiramate at least once (Table 3). At baseline, a total of 20 patients (6.6% of 302 EFF patients) received preventive migraine treatment other than topiramate. The treatment with these drugs continued during the study phase. Due to the low number of patients, no subanalyses was added.

Topiramate dose

At baseline, the majority of patients ($N = 259$, 85.8% of 302 EFF patients) started on the recommended daily dose of 25 mg; 33 patients (10.9% of EFF) started with 50 mg, 6 patients (2.0%) started on 100 mg, and 3 (1.0%) patients started on 200 mg. One patient had an initial dose of 12.5 mg/day. After 6 months of treatment ($N = 261$), 44.4% of patients took a total daily dose of 50 mg, 24.9% took 100 mg/day, and 13.0% took 75 mg/d. The mean daily dose was 58.7 ± 27.4 mg/day at endpoint.

Efficacy outcomes


Number of migraine attacks

The median (IQR) number of migraine attacks per month declined gradually from 4.0 (3.0–6.0) at baseline to 0.9 (0.4–1.8) after 6 months of treatment (Fig. 2a). At the 12-month visit, a further slight improvement was documented.

Table 3 Frequency and type of previous migraine prevention in EFF population (N = 302)

Patients with preventive treatment	139 (46.0)			
Number of therapeutic trials/drugs used	1–2	3–4	5–10	>10
Beta blockers	115 (82.7)	7 (5.0)	1 (0.7)	1 (0.7)
Ca ²⁺ -channel blockers	37 (26.6)			1 (0.7)
Anticonvulsants	23 (16.5)			
Antidepressives	43 (30.9)	2 (1.4)	1 (0.7)	
Other	14 (10.1)	3 (2.2)	1 (0.7)	

Fig. 2 (a) Number of migraine attacks. (b) Number of days with migraine. Asterisk Number of attacks and days were normalized to a period of 28 days



In the overall population, the number of migraine attacks decreased to 0.8 (0.3–2.0) at endpoint. The reduction in migraine attacks was statistically significant compared to baseline at all visits and for the ITT population.

Number of days with migraine

The median (IQR) number of migraine days decreased from 6.0 (5.0–8.0) days at baseline to 1.2 (0.5–2.5) days at month 6 (Fig. 2b). At the end of the follow-up period (month 12), the median (IQR) for migraine days was 0.7 (0.3–1.8) and 0.9 days (0.4–2.7) in the ITT population. The reduction in the number of migraine days was statistically significant compared to baseline ($p < 0.001$) at all visits and for the ITT population. Six patients were identified


who had 15 or more migraine days during their baseline. Due to the small number, no further analyses were done.

Responder rates

Migraine attacks were reduced by at least 50% in 28.1% of patients (i.e. 85 out of 302 patients) after 2 weeks of treatment with topiramate and by at least 75.9% at end of core phase (6 months). Outcomes remained stable during the follow-up phase (month 9: 80.8%, month 12: 79.2%). Results were similar in the ITT population. Here, 76.8% achieved at least 50% reduction in migraine attacks (Fig. 3).

A clinically relevant proportion of patients achieved complete freedom of migraine headaches (100% reduction). The percentage increased from 13.9% after 2 weeks to

Fig. 3 Responder rates for the number of migraine attacks and the mean number of days with migraine. Percentages relate to the number of patients with documented visits. Responder rates for days with migraine headache are not described in the text



18.2%, 21.6%, and 22.1% after 4, 8, and 12 weeks. At the two follow-up visits, the proportion of patients with 100% reduction in migraine attacks reached approximately 21% (month 9: 20.7%, month 12: 20.8%). The calculated LOCF was 21.2%.

Pain intensity scores

Figure 4 illustrates the decrease in the pain intensity score results in the course of the study period. The median (IQR) migraine intensity score decreased in patients with remaining migraine over time. At baseline, a score of 17.0 (12.0–24.0) points was calculated in 294 patients, declining to 12.0 (7.5–19.4) points at week 2 ($N = 257$), 4.6 (2.8–9.3) points at week 8 ($N = 224$), and 3.2 (1.5–6.2) points at month 6 ($N = 228$). During follow-up, further decrease was noted with the lowest value of 2.0 (1.0–5.0) points achieved at month 12 ($N = 142$). The median (IQR) LOCF was 2.6 (1.3–7.0) points ($N = 298$). Changes from baseline were statistically significant ($p < 0.001$) at all visits as well as for the ITT population.

Migraine with aura

At baseline, 81 out of 302 patients (26.8%) reported migraine with aura, 215 patients (71.2%) had no aura, and data were missing for 6 patients (2.0%). During the course of study, the proportion of patients with reported aura decreased. At month 6, only 17 patients (6.5%) and at month 12, only 12 patients (6.6%) reported migraine with aura.

Migraine and menstruation

A subanalyses explored efficacy outcomes in women with and without menstruation associated migraines. Results are based on women's reportings. A distinction between menstruation related migraines (MRM) and pure menstrual migraines (PMM) was not applied [22].

In women without MRM, the median (IQR) monthly number of migraine attacks was 4.0 (3.0–6.0) at baseline ($N = 167$). The median values decreased to 3.7 (2.0–6.0) at week 2 ($N = 163$) and decreased further to 0.9 (0.4–2.0) at month 6 ($N = 147$), and 0.6 (0.3–1.2) at month 12 ($N = 95$). The median LOCF was 0.7 (0.3–2.0; $N = 167$). Changes from baseline were statistically significant ($p \leq 0.002$) at all visits and for the ITT population.

In women with MRM, baseline migraine attack frequency as well as treatment response were similar. The median (IQR) monthly number of migraine attacks was 4.0 (3.0–6.0) at baseline ($N = 96$) and decreased to 2.8 (1.8–6.0) at week 2 ($N = 96$), to 0.9 (0.3–1.6) at month 6 ($N = 80$), and 0.6 (0.0–1.5) at month 12 ($N = 59$). The median LOCF was 0.8 (0.3–2.0; $N = 98$). Changes from baseline were statistically significant ($p \leq 0.024$) at all visits and for the ITT population (Table 4).

Impairment of activities in daily life

The impairment of daily life is illustrated in Fig. 5. The median (IQR) impairment score decreased from 16.0 (12.0–23.0) points at baseline ($N = 294$) to 2.1 (0.7–4.7) points at month 6 ($N = 258$), and further to 1.3 (0.3–3.3) points at month 12 ($N = 172$). The median LOCF was 1.7 (0.3–5.3; $N = 301$). The changes from baseline were statistically significant ($p < 0.001$) at all visits and for the ITT population.

Absenteeism

The mean number of days decreased from 2.1 ± 2.4 days at baseline ($N = 298$) to 1.2 ± 2.6 days at week 2 ($N = 296$), 0.3 ± 0.6 days at month 6 ($N = 257$), and 0.1 ± 0.3 days at month 12 ($N = 172$). Mean LOCF was 0.3 ± 1.0 days ($N = 302$). The changes from baseline were statistically significant ($p < 0.001$) at all visits and for the LOCF.

Fig. 4 Intensity of migraine and other headache in patients with remaining headache. Asterisk Intensity score = (days with severe headache \times 3) + (days with moderate headache \times 2) + (days with slight headache \times 1)




Table 4 Migraine associated with menstruation

	Baseline N = 302	Week 12 N = 272	Month 6 N = 261	Month 9 N = 203	Month 12 N = 183	LOCF N = 235
Patients N (%)						
Women with documented visits ^a	266 (88.1)	240 (88.2)	230 (88.1)	180 (88.7)	164 (89.6)	235 (100)
Women with migraine attacks ^b	259 (97.4)	177 (73.8)	196 (85.2)	134 (74.4)	119 (72.6)	187 (79.6)
Association with menstruation ^c						
No	165 (63.7)	137 (77.4)	145 (74.0)	93 (69.4)	88 (73.9)	
Yes	94 (36.3)	35 (19.8)	45 (23.0)	40 (29.9)	31 (26.1)	42 (22.5) ^d

^a Percentages relate to the number of patients with documented visits

^b Percentages relate to the number of women with documented visits

^c Percentages relate to the number of women with migraine attacks

^d Total count of women for whom migraine attacks associated with menstruation were observed for the first time after treatment with topiramate




Fig. 5 Impairment of daily life. Asterisk Impairment score = (days with severe impairment × 3) + (days with moderate impairment × 2) + (days with slight impairment × 1)

Quality of life (questionnaire HIT-6TM)

At baseline, patients started with clinically relevant impairment as measured by HIT-6TM. The sum score changed from 65.2 ± 4.6 (median: 65.0, IQR: 63.0–68.0; N = 298) to 51.7 ± 8.8 at month 6 (median: 52.0, IQR: 46.0–58.0; N = 254, unknown N = 7), and to 47.5 ± 8.2 at month 12 (median: 48.0, IQR: 40.0–54.0; N = 177, unknown N = 6). The mean LOCF was 48.8 ± 8.8 (median: 48.0, IQR: 42.0–56.0; N = 265). The changes from baseline were statistically significant (p < 0.001) at all time points and for the ITT population LOCF (Fig. 6).

Therapy satisfaction (tolerability and prophylactic efficacy)

The physicians assessed tolerability of topiramate as at least “good” in over 90% of patients (i.e. 97.3% at month 12). The proportion of patients for whom tolerability was rated “very good” increased during the course of the study:




Fig. 6 Quality of life according to the HIT-6TM questionnaire

48.9% (N = 133) at week 12, 51.0% (N = 133) at month 6, and 63.4% (N = 116) at month 12. Tolerability was considered “not satisfactory” for one patient at week 12 (0.4%) and for one patient at month 12 (0.5%). The LOCF (N = 271) yielded very good tolerability for 57.2%, good tolerability for 36.5%, satisfactory tolerability for 5.5%, and not satisfactory tolerability for 0.7% of patients.

Similarly, the physicians assessed the efficacy outcomes of topiramate as at least “good” in over 85% of patients (86.4% at week 12, 94% at month 12). Patients’ assessment was very similar to the physicians’ assessment after 12 weeks of treatment and at the end of the observational period (month 6). The LOCF yielded very good efficacy in 49.8%, good efficacy in 39.1%, satisfactory efficacy in 6.3%, and not satisfactory efficacy in 4.8% out of 271 patients.

Acute medication

During the 28 days prior to treatment with topiramate, patients took triptans at 4.9 ± 3.4 days (median: 5 days,

IQR: 3–7 days, $N = 289$). Other acute migraine medications were taken on average at 9.2 ± 11.5 days (median: 5 days, IQR: 3–12 days, $N = 41$). During the study, the number of acute treatment days declined. At week 2, the mean number of days with triptan treatment had dropped to 3.8 ± 4.8 days (median: 2 days, $N = 286$) and was further decreased to 1.6 ± 3.8 days at month 6 (median: 1 day, $N = 254$) and to 1.0 ± 2.6 days at month 12 (median: 0 days, $N = 163$). On average, other analgetics were used for 1.3 ± 3.0 days at month 6 (median: 0 days; $N = 248$) and 0.9 ± 1.1 days at month 12 (median: 0 days, $N = 163$), while the mean sum of days of all other acute migraine medications was 3.1 ± 5.6 days at month 6 (median: 1 day, $N = 49$) and 1.4 ± 0.8 days at month 12 (median: 1 day, $N = 27$).

Tolerability

In the course of the study, 101 AEs were reported in 46 patients (13.7% of 336 patients) (Table 5). A relationship to treatment with topiramate (possible, or probable, or highly probable) was reported for 64 AEs in 35 patients (10.4%) by the treating physician, including two serious AEs (stroke).

One serious adverse event occurred in a 35-year-old obese woman (BMI 30.8 kg/m²) with known menstruation-associated migraines for 10 years who suffered a cerebrovascular accident on 2nd January 2007. Seriousness was based on medical condition as well as hospitalization. At the time of admission, she was treated with topiramate for 12 weeks and experienced improvement in migraine headache frequency as well as associated symptoms. The patient took her last dose the day prior to her insult. The patient had a history of radiation and chemotherapy for Hodgkińs disease in 1989. Based on the physician's

Table 5 Summary of adverse events

	All patients N (%)
Number of patients treated	336
All adverse events	
Number of adverse events	101
Patients with adverse events	46 (13.7)
Patients with serious adverse events	2 (0.6)
Number of deaths	0 (0.0)
Related adverse events	
Number of adverse events	64
Patients with adverse events	35 (10.4)
Patients with serious adverse events	1 (0.3)
Number of deaths	0 (0.0)

Percentages relate to patients dosed

Related = possible + probable + likely relationship with topiramate

Table 6 Number of patients with reported adverse events (AEs) during the whole study (safety-sample)

	Total			
	All AEs		AEs with CR ^a	
	N	%	N	%
At least one AE ^b	46	13.7	35	10.4
At least one AE from the following class ^b				
Paraesthesia	10	3.0	9	2.7
Dizziness	4	1.2	4	1.2
Diarrhea	5	1.5	4	1.2
Nausea	14	4.2	8	2.4
Fatigue	4	1.2	4	1.2
Vomiting	4	1.2	1	0.3

Listed are adverse events occurring in >3 patients in the total sample

^a AEs with possible, probable, or very probable causal relationship (CR) with topiramate as assessed by the investigator

^b Multiple events possible

assessment, the SAE was considered as being “possibly” related to topiramate therapy. No further cardio-vascular risk factors were identified. The patient had not fully recovered at the time of the conclusion of the study report. She has been discharged to a rehabilitation center.

The second patient was a 52-year-old woman with a history of episodic migraine for the last 20 years who presented with weight loss. Subsequently, the patient was diagnosed with pituitary insufficiency secondary to a craniopharyngeoma and underwent microsurgical removal. The relationship to topiramate therapy was rated as unlikely. No deaths occurred during the study.

As shown in Table 6, the most frequently reported symptoms were nausea (total: $N = 14$, 4.2%; related: $N = 8$, 2.4%), paresthesia (total: $N = 10$, 3.0%; related: $N = 9$, 2.7%), and vomiting ($N = 4$, 1.2%). Adverse events reported only in few patients were: fatigue (total and related: $N = 4$, 1.2%), diarrhea (total: $N = 5$, 1.5%, related: $N = 4$, 1.2%), and dizziness (total and related: $N = 4$, 1.2%). All other symptoms were reported by <3 patients.

The mean weight of the patients was stable in the course of the study. At baseline, the mean weight of the 302 patients was 68.6 ± 11.3 kg (median: 67 kg, IQR range 60–75 kg). At the end of the follow-up period (month 12) the mean weight of the remaining 183 patients was 68.1 ± 10.5 kg (median: 68 kg, IQR: 60–74 kg).

Discussion

In this open label study, tolerability and efficacy outcomes of topiramate for preventive migraine therapy were explored in 336 patients seen in private practices or

ambulatory care centers. These practitioners are important for successful management of the majority of migraine patients who do not require pain management in a tertiary care center. Both, tolerability and efficacy results in this setting compare well to published data of controlled and open label trials conducted in specialized academic institutions [12, 13, 23, 24].

In 35 patients (10.4%), at least one treatment-related AE were reported. The most frequent AE was paresthesia in 10 patients (3.0%). In previous controlled trials, paresthesia was also the most common topiramate-associated AE (35%, 51%, and 49% of patients receiving topiramate 50 mg/day, 100 mg/day, or 200 mg/day, respectively [6% on placebo]), and thus, higher compared to this study [13, 24, 25]. Incidence of paresthesias in patients treated with topiramate, however, vary considerably across studies with generally lower frequencies in open-label compared to controlled studies. In a recent open label study of topiramate in epilepsy patients, paresthesia was observed in 8.0% of patients [26]. The other important AE of this study was nausea (4.2%). All other symptoms of AEs (Table 6), such as fatigue (1.2%), dizziness (1.2%), impaired attention (0.9%), anorexia (0.9%), and weight loss (0.6%) occurred less frequently. In a pooled analysis of randomized controlled trials, similar frequencies were observed for nausea (8.9%), fatigue (11.8%), dizziness (9.7%), and weight loss (1.3%). Topiramate-associated AEs are mild or moderate in severity and occur at consistently higher rates during the titration period compared to the maintenance period of the double-blind phase. Paresthesia, nausea fatigue, and dizziness were also commonly reported AEs in a recent large open label study of topiramate in migraine prevention [21]. The discontinuation rate during the 6 months core phase due to AEs was low. Overall, 77.7% of all patients completed the 6 months core phase. Among 75 patients who discontinued prematurely (22.3% of SAF), 7 patients (2.1%) had AEs. The most frequent symptoms in these patients were fatigue and nausea, each reported for two patients, respectively. In almost 75% of patients the reason for discontinuation is unknown and no further information was obtainable. Even if all of these patients discontinued due to adverse events, the effectiveness and retention on treatment compares well to other open label studies and provides additional support for the ease of use and tolerability of topiramate in daily routine for migraine prevention.

As much as 183 patients (54.5% of SAF) completed the full 12-months observation and follow-up period) including Visit 8. Treatment discontinuation due to AE in previous controlled studies with topiramate was higher, likely due to higher doses in those studies as well as fixed titration schedule [25]. AE-related drop-outs were dose-dependent in all randomized controlled trials [25, 27].

The lower incidence of commonly reported AE's with topiramate and AE-related discontinuation rate of this study is likely due to the lower average daily dose of 57.8 mg topiramate in this study as well as the individualized treatment approach. The 6 months follow up period was optional and reasons for treatment continuation were not formally assessed. The study was conducted at a time when several treatment guidelines recommended discontinuation of preventive therapy after 3–6 months [28]. This has to be contrasted to clinical practice. In some patients, longer treatment continuation might be beneficial. A recently published double-blind placebo controlled study supports this view by showing continued benefit of therapy for 6 months to up to one year [12]. Recently published data even suggest that approximately 50% of patients might actually benefit from migraine prevention for more than one year [29]. The number of patients who might qualify for a diagnosis of chronic migraine was low, therefore, a subanalyses of treatment response in this patient group was not performed. Recent data suggest that topiramate is effective in chronic migraine treatment [41].

The study population was predominantly female (87%, SAF). Based on epidemiological data, a higher proportion of men would be expected [2, 30]. An explanation might be the lower rate of diagnosis in men compared to women which is suggested by the American migraine study. Though close to 50% of affected individuals are diagnosed, the proportion of men with a diagnosis reaches only 30% [31]. In addition, as shown in the American migraine prevalence and prevention study, current or ever use of preventive medication was more likely in women than in men (odds ratio [OR] = 1.37, 95% confidence interval [CI] 1.27–1.48), increased with age and individuals with high MIDAS grade (Grade IV vs. I, OR 2.35, 95% CI 2.09–2.64) [32]. In addition, a higher rate of vocational activity among men may result in limited interest to participate in an open label study resulting in an artificially low number of participants. Post-hoc analyses based on the pivotal trials do not suggest a differential response in women or men as another possible explanation [24].

After 6 months of treatment, patients receiving topiramate had less than one migraine attack per month. The median number of migraine attacks declined from 4.0 to 0.9. The preventive treatment effect was maintained throughout the follow-up phase. The number of migraine days per month was also significantly reduced. Treatment with topiramate was also associated with significant improvements for several other migraine treatment effect measures, such as pain intensity and consumption of analgesics. At the end of the 6 months core phase, the frequency of migraine attacks could be reduced by at least 50% compared to baseline for 76% of patients. The proportion of patients with more than 50% migraine reduction

reached 80% during the follow-up period. As much as 21% of all patients were completely free of migraine attacks at the end of the follow-up phase.

The efficacy data of this study are comparable with those of randomized controlled trials. Brandes reported a 40% reduction in migraine frequency for daily doses of 100 mg and a 42% reduction for daily doses of 200 mg at 6 months endpoint [25]. Similar reduction rates were also observed in other controlled trials [13]. Results from these placebo-controlled trials, however, suggest that even total daily doses at 50 mg might have a significant effect compared to placebo or show at least incremental benefit. In this study, topiramate was dosed between 25 and 200 mg/day with a mean daily dose of 58.7 ± 27.7 mg, indicating that reduction of migraine days and pain intensity can be achieved with lower levels of topiramate.

Menstrual migraine was observed in 36% of female migraineurs which is lower than the 50% expected based on epidemiological data [33]. In this subgroup of women in our study, a clinically relevant reduction of migraine attacks after 6 months was observed. Compared to non-menstrual migraine, menstrual migraine attacks are often more severe, longer in duration, and have a poorer response to analgesics. Epidemiological, pathophysiological, and clinical evidences link estrogen to migraine headaches [34, 35]. For the preventive treatment of menstrual migraine, there are grade B recommendations for the perimenstrual use of transcutaneous estrogen 1.5 mg. Also, frovatriptan 2.5 mg twice daily and naratriptan 1 mg twice daily have shown efficacy in prevention of menstrual migraine [22]. None of these agents was used in our patients. Even considering the limitations of this study by not having defined menstruation-related migraines according to the international headache society criteria [22], these data may suggest that menstrual migraine attacks respond to preventive treatment with topiramate. A post-hoc analyses based on a recently published trial is supportive of this view [12].

We also observed significant improvement on measurements of daily living activities and health related quality of life. In the course of the 12-month study period, the median impairment score decreased from 16.0 to 1.3 points and the HIT-6TM score sum decreased from 65.0 to 48.0 points. The improvement of functional outcome with topiramate migraine prophylaxis is exemplified by the reduction of days absent from work (from a median of 2.0 days per month at baseline to 0.0 days after treatment). Similar observations have been reported from other studies using health-related quality of life endpoints, such as Migraine Specific Questionnaire (MSQ) and the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) [36]. In a 3-month prospective study of 103 migraine patients, for example, all SF-36 items improved after patients were started on pharmacologic migraine prophylaxis [37].

Improved health-related quality of life outcome and vocational activities are prime objectives of preventive migraine therapy. Preventive therapy with topiramate was shown to be associated with significant decreases in resource use based on pharmacy data claim analyses [9] as well as an increased work place productivity based on results of randomized controlled trials [38].

The observed treatment effects of an open label study need to be interpreted with caution. Several controlled studies have demonstrated a powerful placebo-effect in migraine prevention [39]. In one meta-analysis of all placebo-controlled studies of propranolol for prevention of migraine, the response rate for propranolol was 55.1% and for placebo 14.3% [40]. A very recent meta-analysis reported placebo responder rates of 21%. In the current study, the extent of reduction in migraine attacks, migraine days, maximum pain intensity, and consumption of analgesics, however, is comparable to responder rates of active substances in controlled studies. Therefore, the improved migraine control observed in this study cannot be attributed to a placebo effect alone.

The results of the current study further support that topiramate is generally well tolerated and effective in migraine prevention when administered by non-specialized physicians. Topiramate showed significant reduction in the frequency of migraine attacks, migraine days, pain intensity, and improvement on health-related quality of life outcomes. These results may spur the effort to improve the current underutilization of pharmacologic migraine prevention outside tertiary or specialized care.

Acknowledgments We thank the study coordinators from Janssen-Cilag, Germany for their contribution and Kerstin Schuppien and Tanja Hendrichs, PhD, for editorial assistance with the manuscript.

Conflict of interest Dr. Bornhoevd and Dr. Schauble are full time employees of Janssen-Cilag EMEA, Neuss, Germany. The study was conducted by Medidata, Konstanz, Germany and Dr. Fritzsche served as a consultant for the statistical analysis. The study has been sponsored by Janssen-Cilag Germany.

Appendix

We gratefully acknowledge the participation of following TOPMAT-MIG-0001 investigators: Thomas Wegner, Königstein; Hans Werner Fischer, Friedrichsthal; Bernhard Wolfram, Mannheim; Karin Schindlbeck, Parsberg; Susanne Peters, Dortmund; Ursula Schax, Essen; Eva M. Dietz, Bamberg; Juergen Haas, Nürnberg; Markus Föh, Fulda; D. Katholnigg, Mönchengladbach; Gerd Rauch, Bayreuth; Martin Kühn, München; Veit-Ulrich Becker, Hamburg; Michael Springer, Pirmasens; Guido M. Auner, Lüdenscheid; Kristin Hontzek, Dommitzsch; Heinz-Wilhelm

Kaune, Lohfelden; Volker Schreibmüller, Barsinghausen; Svetlana Liadski, Essen; B. Wiedeking, Essen; Michael Rengeling, Petershagen; Volker Henning, Oberdorla; Barbara Walaschewski, Grabowhöfe; Roland J. Schätzl, Großheirath; Barbara Steinbrück, Stuttgart; Henner Reineke, Stuttgart; Sven Rönnebeck, Hedersleben; Tobias Armbruster, Heilbronn; Roland J. Schätzl, Ebersdorf; Anke Tiedt, Claußnitz; Tim Hördt, Bielefeld; Frank Eisenkrätzer, Radebeul; Rainer Waldmann, Stuttgart; Petra Sandow, Berlin; Bernd Metzger, Stuttgart; Anja Eckert, Leipzig; Nader Kayali, Dorsten; Michael Lang, Ulm; Harald Klein, Darmstadt; Hilmar Böneke, Lienen; Christoph Schiel, Giessen; Matthias Eyck, Berlin; Hans-Dieter Gross, Limburg; Andreas Beck, München; Bernd Spengruber, Wangen im Allgäu; Markus Schulz-Meentzen, Bremen; Arnulf Gruber, Brensbach; Andrea Rubbel-Ehle, Niebuell; Bernd Porrmann, Baden-Baden; Marius Unger, Giengen an der Brenz; Klaus-Peter W. Schaps, Wilhelmshaven; Helmut Stienker-Fisse, Remscheid; Gabriele Meyer, Berlin; Alexander Matuschke, Weyhe; Heike Eckardt, Gütersloh; Ursula Jansen, Pulheim; Katy Klook, Rostock; Mirko Witteborn, Halberstadt; Theresia Roidl, Schwandorf; Katharina Farke-Rämer, Berlin; Michael Dietlein, Augsburg; Peter Möller, Marl; Winfried Hofmann, Marburg; Suso Lederle, Stuttgart; Frank Wiedemann, Kandern-Wollbach; Ursula Rieser, Bärnau; Martin L.J. Wimmer, München; Christa Enderle, Riedlingen; Detlef Gottesbüren, S.g.münd; Thomas Weber, Haren; Manfred Oberling, Bad Camberg; Werner Flöhl, Paderborn; Nenad Martinovic, Eheine; Wolfgang Köller, Berlin; Bärbel Jersch, Schönebeck; Heidrun Adam, Rostock; Olaf Carstensen, Eckernförde; Kerstin Franke, Berlin; Norbert Martini, Gechingen; Hildegard Schneider-Nutz, Köln; Eberhard Bek, Langenbrettach; Birgit Magnus-Ellenbroek, Emmerich; Borries Kukowski, Göttingen; Uwe Jorns, Trossingen; Tatjana Kelch, Dresden; Günther Endrass, Grünstadt; Rainer Katzfuss, Sommerhausen; Lukas Schmitt, Hamburg; Frank Kühn, Oranienburg; Hanns-Joachim Schietsch, Augsburg; Hans D. Diery, Butzbach; Doris Wiese-Junginger, Planegg; Freia Guse-Grosse, Jülich; Jens Thonack, Greifswald; Peter Franz, Berlin; Regina Dauwe, Ettlingen; Uwe Gerbaulet, Löhne; Sabine Koller, Saerbeck; Eva Freitag, Berlin; Reinhard Krug, Ulm; Berthold Jonas, Essen; Alfons Linke, Tübingen; Achim Ulmer, Ludwigsburg; Sigmund Jakob, Weinsberg; Volker Gillwald, Mönchengladbach; Mario Tomm, Heek; Nikolaos Ampatziadis, Wiesbaden; Josip Udovic, München; Christa Koßler-Wiesweg, Essen; Knut-Olaf Brose, Syke; Hans-Peter Westfal, Göttingen; Radu Dan Noveanu, Leonberg; Cornelia Jacob, Lippersdorf; Vilém Fuchs, Köln; Axel Althen, Hainburg; Andreas Lang, Wilhelmshaven; Rupert Lebmeier, Zweibrücken; Karl Friedrich Beykirch, Frankfurt; Steve Müller, Güglingen; Gerhard Krehan, Graben-Neudorf; Robert Ivancic,

Gersthofen; Andrea Eichhorn, Wadgassen; Felix Lion, Volkmarsen; Arkadius Misera, Düsseldorf; Christian Nowack, Durmersheim; Andre Wagner, Teutschenthal; Manfred Böger, Castrop-Rauxel; Stefan Ries, Erbach; Klaus Hachenberg, Gütersloh; Peter Pickert, Frankfurt; Marianne Lang, Neckargemünd; Volker Strick, Köln; Anneliese Lüdtke, Neu-Ulm; Maria Siemer, Haselünne; Sinta Setiawan, Nordhorn; Gabriele Feuerstack, Heikendorf; Axel Müller, Magdeburg; Senta Kim-Giesemann, Friesoythe; D. Noack, Limburgerhof; Barbara Unsorg, Erbach; Rainer Busch, Münchweiler; Klaus Weischer, Rheine; Christoph Stenzel, Köln; Christian Albrecht, Hasbergen; Ulrich Assmann, Weil am Rhein; Maria Wegner, Viernheim; Holger Hufnagel, Neckarbischofsheim; Marco Loddo, Rastede; Lutz-Dieter Lohse, Dresden; Wolfgang Derissen, Mönchengladbach; Bernd Junge, Uttenreuth; Frank Seidel, Wiefelstede; Harald Bannies, Solingen; Imke Hanoldt, Stolberg; Rainer Bachus, Berlin; Eva Burger-Deinerth, Berlin; Hoang Ha-Phuoc, Olpe; Memet Gülbeyaz, Hamburg; Gunter Brauer, Cottbus; Wolfgang Leps, Berlin; Faizurrahman Ahrari, Hamburg; Stephan Lode, Hückeswagen; Christian Brandt, Gronau; Rolf Zimmermann, Dessau; Andreas Böhme, Delitzsch; Markus Bruckhaus-Walter, Herne; Udo Philipp, Berlin; Ulrich Loel, Salzgitter; Michael Bruch, Herne; Kerstin Schulze, Norderstedt; Steffen Christian Kohl, Dessau; Reinhard Lakony, Berlin; Marion Nesimi, Wildau; Hans-Dieter Zug, Böblingen; Serena Scarel, Unterhaching; Ulrich G. Schultheiß, Sigmaringen; Sibylle Berdermann-Welz, Altenburg; Walter Freudenstein, Braunschweig; Regine Schmitt, Nußbach; Angelika Christopher, Berlin; Uwe Patzelt, Seelow; Doris Augustin-Reuss, Solingen; Karl-Otto Sigel, Unterhaching.

References

1. Bigal ME, Lipton RB (2009) The epidemiology, burden, and comorbidities of migraine. *Neurol Clin* 27:321–334
2. Jensen R, Stovner LJ (2008) Epidemiology and comorbidity of headache. *Lancet Neurol* 7:354–361
3. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007) Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology* 68:343–349
4. Lipton RB, Bigal ME (2005) The epidemiology of migraine. *Am J Med* 118(Suppl 1):3S–10S
5. Halpern MT, Lipton RB, Cady RK, Kwong WJ, Marlo KO, Batenhorst AS (2002) Costs and outcomes of early versus delayed migraine treatment with sumatriptan. *Headache* 42:984–999
6. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML (1999) Burden of migraine in the United States: disability and economic costs. *Arch Intern Med* 159:813–818
7. Buse DC, Rupnow MF, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. *Mayo Clin Proc* 84:422–435

8. Silberstein SD, Goadsby PJ, Lipton RB (2000) Management of migraine: an algorithmic approach. *Neurology* 55:S46–S52
9. Silberstein SD, Feliu AL, Rupnow MF, Blount AC, Bocuzzi SJ (2007) Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. *Headache* 47:500–510
10. Diener HC, Brune K, Gerber WD, Pfaffenrath V, Straube A (2000) Therapy of the acute migraine attack and migraine prophylaxis. Recommendation of the “Deutsche Migräne- und Kopfschmerz-Gesellschaft. *Schmerz* 14:269–283
11. Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J (2009) Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. *Clin Ther* 31:542–559
12. Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Del Rio MS, Schoenen J, Schwalen S, van Oene OJ (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 6:1054–1062
13. Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ, Neto W, Vijapurkar U, Doyle A, Jacobs D (2004) Topiramate in migraine prophylaxis—results from a placebo-controlled trial with propranolol as an active control. *J Neurol* 251:943–950
14. Diener HC, Matias-Guiu J, Hartung E, Pfaffenrath V, Ludin HP, Nappi G, De Beukelaar F (2002) Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. *Cephalalgia* 22:209–221
15. Silberstein SD (2004) Topiramate in migraine prevention: evidence-based medicine from clinical trials. *Neurol Sci* 25(Suppl 3): S244–S245
16. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL (1995) Migraine prophylaxis with divalproex. *Arch Neurol* 52:281–286
17. Pascual J, Leira R, Lainez JM (2003) Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. *Cephalalgia* 23:961–962
18. Silberstein SD, Hulihan J, Karim MR, Wu SC, Jordan D, Karvois D, Kamin M (2006) Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. *Clin Ther* 28:1002–1011
19. Brandes JL (2002) Global trends in migraine care: results from the MAZE survey. *CNS Drugs* 16(Suppl 1):13–18
20. Lanteri-Minet M (2008) The role of general practitioners in migraine management. *Cephalalgia* 28(Suppl 2):1–8
21. Nelles G, Delbrück A, Schulze I, Kademann B, Bornhoevd K, Schäfer S, Schauble B (2009) Topiramate for migraine prevention in a naturalistic setting—results from an open label, flexible dose study. *Headache* [Epub ahead of print]
22. Pringsheim T, Davenport WJ, Dodick D (2008) Acute treatment and prevention of menstrually related migraine headache: evidence-based review. *Neurology* 70:1555–1563
23. Rapoport A, Mauskop A, Diener HC, Schwalen S, Pfeil J (2006) Long-term migraine prevention with topiramate: open-label extension of pivotal trials. *Headache* 46:1151–1160
24. Bussone G, Diener HC, Pfeil J, Schwalen S (2005) Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. *Int J Clin Pract* 59:961–968
25. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwabe S, Jacobs D (2004) Topiramate for migraine prevention: a randomized controlled trial. *JAMA* 291:965–973
26. Kurth C, Schauble B, Schreiner A, Rettig K, Steinhoff BJ (2009) Exploring efficacy and tolerability outcomes in patients with difficult-to-treat epilepsy receiving adjunctive topiramate at different titration rates—an exploratory study. *Acta Neurol Scand* 120:80–87
27. Silberstein SD, Neto W, Schmitt J, Jacobs D (2004) Topiramate in migraine prevention: results of a large controlled trial. *Arch Neurol* 61:490–495
28. Treatment Guideline Subcommittee of the Taiwan Headache Society (2008) Treatment guidelines for preventive treatment of migraine. *Acta Neurol Taiwan* 17:132–148
29. Pascual J, El BY, Gomez-Sanchez JC (2007) How many migraine patients need prolonged (> 1 year) preventive treatment? Experience with topiramate. *J Headache Pain* 8:90–93
30. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. *Headache* 41:646–657
31. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF (2001) Migraine diagnosis and treatment: results from the American Migraine Study II. *Headache* 41:638–645
32. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB (2007) Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. *Headache* 47:355–363
33. Martin VT, Lipton RB (2008) Epidemiology and biology of menstrual migraine. *Headache* 48(Suppl 3):S124–S130
34. MacGregor EA (1997) Menstruation, sex hormones, and migraine. *Neurol Clin* 15:125–141
35. MacGregor EA (1996) “Menstrual” migraine: towards a definition. *Cephalalgia* 16:11–21
36. Brandes JL, Kudrow DB, Rothrock JF, Rupnow MF, Fairclough DL, Greenberg SJ (2006) Assessing the ability of topiramate to improve the daily activities of patients with migraine. *Mayo Clin Proc* 81:1311–1319
37. D’Amico D, Lanteri-Minet M (2006) Migraine preventive therapy: selection of appropriate patients and general principles of management. *Expert Rev Neurother* 6:1147–1157
38. Lofland JH, Gagne JJ, Pizzi LT, Rupnow M, Silberstein SD (2007) Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials. *J Occup Environ Med* 49:252–257
39. Diener HC, Schorn CF, Bingel U, Dodick DW (2008) The importance of placebo in headache research. *Cephalalgia* 28:1003–1011
40. Holroyd KA, Penzien DB, Cordingley GE (1991) Propranolol in the management of recurrent migraine: a meta-analytic review. *Headache* 31:333–340
41. Diener HC, Dodick DW, Goadsby PJ, Bigal ME, Bussone G, Silberstein SD, Mathew N, Ascher S, Morein J, Hulihan JF, Biondi DM, Greenberg SJ (2009) Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. *Cephalalgia* 29(10):1021–1027